- Home
- AEMD vs TOVX Comparison
AEMD vs TOVX Comparison
Compare AEMD & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEMD
- TOVX
- Stock Information
- Founded
- AEMD 1984
- TOVX 2001
- Country
- AEMD United States
- TOVX United States
- Employees
- AEMD N/A
- TOVX N/A
- Industry
- AEMD Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- AEMD Health Care
- TOVX Health Care
- Exchange
- AEMD Nasdaq
- TOVX Nasdaq
- Market Cap
- AEMD 3.8M
- TOVX 3.8M
- IPO Year
- AEMD N/A
- TOVX 2006
- Fundamental
- Price
- AEMD $5.43
- TOVX $0.33
- Analyst Decision
- AEMD Buy
- TOVX Hold
- Analyst Count
- AEMD 2
- TOVX 1
- Target Price
- AEMD $287.50
- TOVX N/A
- AVG Volume (30 Days)
- AEMD 64.7K
- TOVX 42.8M
- Earning Date
- AEMD 11-12-2025
- TOVX 11-11-2025
- Dividend Yield
- AEMD N/A
- TOVX N/A
- EPS Growth
- AEMD N/A
- TOVX N/A
- EPS
- AEMD N/A
- TOVX N/A
- Revenue
- AEMD N/A
- TOVX N/A
- Revenue This Year
- AEMD N/A
- TOVX N/A
- Revenue Next Year
- AEMD N/A
- TOVX N/A
- P/E Ratio
- AEMD N/A
- TOVX N/A
- Revenue Growth
- AEMD N/A
- TOVX N/A
- 52 Week Low
- AEMD $4.65
- TOVX $0.28
- 52 Week High
- AEMD $84.40
- TOVX $2.64
- Technical
- Relative Strength Index (RSI)
- AEMD 76.89
- TOVX 43.85
- Support Level
- AEMD $4.65
- TOVX $0.30
- Resistance Level
- AEMD $5.49
- TOVX $0.85
- Average True Range (ATR)
- AEMD 0.25
- TOVX 0.11
- MACD
- AEMD 0.43
- TOVX -0.02
- Stochastic Oscillator
- AEMD 84.62
- TOVX 6.36
About AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.